Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation

BCL-2 family proteins are frequently aberrantly expressed in mantle cell lymphoma (MCL). Recently, the BCL-2-specific inhibitor venetoclax has been approved by the US Food and Drug Administration for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). In MCL, venetoclax has shown pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haematologica (Roma) Jg. 108; H. 3; S. 797 - 810
Hauptverfasser:	Thus, Yvonne J., De Rooij, Martin F.M., Swier, Nathalie, Beijersbergen, Roderick L., Guikema, Jeroen E.J., Kersten, Marie-José, Eldering, Eric, Pals, Steven T., Kater, Arnon P., Spaargaren, Marcel
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Italy Fondazione Ferrata Storti 01.03.2023 Ferrata Storti Foundation
Schlagworte:	Adult Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - pharmacology Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Casein Kinase II - genetics Casein Kinase II - metabolism Cell Line, Tumor Down-Regulation Humans Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - genetics Lymphoma, Mantle-Cell - metabolism Myeloid Cell Leukemia Sequence 1 Protein - metabolism Non-Hodgkin Lymphoma Proto-Oncogene Proteins c-bcl-2
ISSN:	0390-6078, 1592-8721, 1592-8721
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!